MX355088B - Inhibidores de tienopirimidina de proteina cinasa c atipica. - Google Patents

Inhibidores de tienopirimidina de proteina cinasa c atipica.

Info

Publication number
MX355088B
MX355088B MX2014006233A MX2014006233A MX355088B MX 355088 B MX355088 B MX 355088B MX 2014006233 A MX2014006233 A MX 2014006233A MX 2014006233 A MX2014006233 A MX 2014006233A MX 355088 B MX355088 B MX 355088B
Authority
MX
Mexico
Prior art keywords
protein kinase
atypical protein
thienopyrimidine
inhibitors
thienopyrimidine inhibitors
Prior art date
Application number
MX2014006233A
Other languages
English (en)
Spanish (es)
Other versions
MX2014006233A (es
Inventor
D Dorsey Bruce
S Learn Keith
L Morris Emma
R Ott Gregory
R Roffey Jonathan
N Soudy Christellen
C Wagner Jason
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of MX2014006233A publication Critical patent/MX2014006233A/es
Publication of MX355088B publication Critical patent/MX355088B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014006233A 2011-11-23 2012-11-19 Inhibidores de tienopirimidina de proteina cinasa c atipica. MX355088B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563310P 2011-11-23 2011-11-23
PCT/US2012/065831 WO2013078126A1 (en) 2011-11-23 2012-11-19 Thienopyrimidine inhibitors of atypical protein kinase c

Publications (2)

Publication Number Publication Date
MX2014006233A MX2014006233A (es) 2014-10-17
MX355088B true MX355088B (es) 2018-04-04

Family

ID=47295200

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006233A MX355088B (es) 2011-11-23 2012-11-19 Inhibidores de tienopirimidina de proteina cinasa c atipica.

Country Status (11)

Country Link
US (3) US9604994B2 (OSRAM)
EP (2) EP2782917B1 (OSRAM)
JP (1) JP6206926B2 (OSRAM)
CN (1) CN104053661B (OSRAM)
AU (2) AU2012340869B2 (OSRAM)
CA (1) CA2855446C (OSRAM)
ES (1) ES2575143T3 (OSRAM)
IL (1) IL232559B (OSRAM)
IN (1) IN2014CN04558A (OSRAM)
MX (1) MX355088B (OSRAM)
WO (1) WO2013078126A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN104582705A (zh) * 2012-01-10 2015-04-29 林伯士艾瑞斯公司 白介素-1受体相关激酶(irak)抑制剂和其用途
CN104902959A (zh) 2012-07-11 2015-09-09 林伯士艾瑞斯公司 Irak抑制剂和其用途
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
AU2014205577A1 (en) 2013-01-10 2015-05-28 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
EP3049086A4 (en) 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
TWI675836B (zh) * 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶c之氮雜喹唑啉抑制劑
AU2016378723B2 (en) 2015-12-22 2021-09-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
KR20180075228A (ko) * 2016-12-26 2018-07-04 한미약품 주식회사 싸이에노피리미딘 화합물의 신규 제조방법 및 중간체
MA49458A (fr) 2017-06-21 2020-04-29 SHY Therapeutics LLC Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
WO2019119206A1 (en) * 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CN108658999B (zh) * 2018-04-24 2021-02-05 温州大学 2-苯基杂环并[2,3-d]嘧啶-4(3H)-酮类化合物的合成方法
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
WO2020106825A1 (en) 2018-11-20 2020-05-28 Georgetown University Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3725788A1 (en) * 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
CN116410205B (zh) * 2021-12-29 2024-07-05 上海皓元生物医药科技有限公司 一种3-取代-9-甲基-噻吩并三唑并噁嗪类化合物的制备方法
CN116925098A (zh) * 2022-04-09 2023-10-24 深圳湾实验室 靶向泛素特异性蛋白酶1(usp1)的小分子抑制剂及其应用
WO2025085725A1 (en) * 2023-10-20 2025-04-24 Scorpion Therapeutics, Inc. Methods for treating a p53-associated cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
TW564247B (en) 1999-04-08 2003-12-01 Akzo Nobel Nv Bicyclic heteraromatic compound
CZ20021086A3 (cs) 1999-09-30 2002-10-16 Neurogen Corporation Alkylendiaminem substituované heterocykly
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AU2001290311A1 (en) 2000-09-29 2002-04-08 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
MXPA04005510A (es) 2001-12-07 2006-02-24 Vertex Pharma Compuestos basados en pirimidina utiles como inhibidores de gsk-3.
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
TW200410975A (en) 2002-09-26 2004-07-01 Nihon Nohyaku Co Ltd New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
KR101186678B1 (ko) 2003-06-11 2012-09-27 젠션 리미티드 포타슘 채널 억제제로서의 티에노피리미딘 유도체
US20050187389A1 (en) 2004-01-13 2005-08-25 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
JP5055564B2 (ja) 2004-06-15 2012-10-24 メルク・シャープ・エンド・ドーム・コーポレイション Rna依存性rnaウイルスポリメラーゼの阻害剤としてのc−プリンヌクレオシド類似体
WO2006093518A2 (en) 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
WO2006010568A2 (de) 2004-07-23 2006-02-02 Curacyte Discovery Gmbh Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung
DE102005013621A1 (de) 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
PT2041139E (pt) 2006-04-26 2012-01-13 Hoffmann La Roche Compostos farmacêuticos
WO2008037607A1 (de) 2006-09-25 2008-04-03 Basf Se Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
WO2008073785A2 (en) * 2006-12-07 2008-06-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
CA2725220C (en) 2008-05-30 2018-07-31 Mitologics Pyrimidinones and pyrimidines derivates as ant-ligands molecules and biological applications
ME02230B (me) * 2009-01-08 2016-02-20 Curis Inc Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
BR112012010186B8 (pt) 2009-10-29 2021-05-25 Palau Pharma Sa derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
EP2557923A4 (en) * 2010-04-16 2013-10-23 Curis Inc TREATMENT OF CANCER DISORDERS WITH K-RAS MUTATIONS

Also Published As

Publication number Publication date
AU2012340869B2 (en) 2017-03-02
CA2855446A1 (en) 2013-05-30
US20140323435A1 (en) 2014-10-30
JP2014533728A (ja) 2014-12-15
AU2017203725B2 (en) 2019-02-28
CN104053661B (zh) 2018-06-19
NZ625447A (en) 2015-09-25
IL232559A0 (en) 2014-06-30
MX2014006233A (es) 2014-10-17
CA2855446C (en) 2021-04-20
EP3048106A1 (en) 2016-07-27
US10183950B2 (en) 2019-01-22
HK1202529A1 (zh) 2015-10-02
US20190106433A1 (en) 2019-04-11
EP3048106B1 (en) 2019-11-06
AU2012340869A1 (en) 2014-06-19
WO2013078126A1 (en) 2013-05-30
IL232559B (en) 2018-04-30
US20170158706A1 (en) 2017-06-08
EP2782917B1 (en) 2016-03-02
US9604994B2 (en) 2017-03-28
ES2575143T3 (es) 2016-06-24
CN104053661A (zh) 2014-09-17
AU2017203725A1 (en) 2017-06-22
EP2782917A1 (en) 2014-10-01
JP6206926B2 (ja) 2017-10-04
IN2014CN04558A (OSRAM) 2015-09-18
US10954251B2 (en) 2021-03-23

Similar Documents

Publication Publication Date Title
MX355088B (es) Inhibidores de tienopirimidina de proteina cinasa c atipica.
PH12015500689B1 (en) Azaquinazoline inhibitors of atypical protein kinase c
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
MY199894A (en) Prmt5 inhibitors and uses thereof
UA111382C2 (uk) Інгібітори протеїнкінази
MY162167A (en) Substituted acetyl-coa carboxylase inhibitors
PH12014500883A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
MY172924A (en) Neprilysin inhibitors
PH12014500373A1 (en) Amino quinazolines as kinase inhibitors
EA201492210A1 (ru) Соединения, ингибирующие активность катехол-o-метилтрансферазы
PH12014501979B1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
MX2015009678A (es) Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).
UA109932C2 (xx) Циклопропіламіни як інгібітори lsd1

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CANCER RESEARCH TECHNOLOGY LIMITED

FG Grant or registration